Approval · Notice of Compliance 2122 · 2001
COREG: Notice of Compliance 2122
Issued June 22, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2122
- Date
- June 22, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change in manufacturer name
- Therapeutic class
- Congestive heart failure agent
Products in this notice
Medicinal ingredients
- CARVEDILOL 3.125 MG per TAB
- CARVEDILOL 6.25 MG per TAB
- CARVEDILOL 12.5 MG per TAB
- CARVEDILOL 25 MG per TAB